CD274 and cancer: The FDA have approved immune checkpoint inhibitors (ICIs) against cytotoxic T-lymphocyte-associated antigen (CTLA-4), programmed cell death receptor 1 (PD-1), and programmed cell death 1 ligand 1 (PD-L1) for treatment in many types of cancers [11].